Table 1 Characteristics of patients with CML-BC.
Number of cases | 136 |
Age at BC diagnosis (y), median (range) (n = 126) | 50 (16–86) |
Sex, n (%) (n = 132) |  |
  Male | 79 (59.8) |
  Female | 53 (40.2) |
Lineage of blasts, n (%) (n = 129) |  |
  Myeloid | 81 (62.8) |
  Lymphoid | 48 (37.2) |
WBC (×103/uL), median (range) (n = 123) | 40,600 (1700–580,000) |
Hb (g/dL), median (range) (n = 123) | 9.6 (5.0–15.8) |
PLT (×103/uL), median (range) (n = 123) | 105,000 (3000–2,740,000) |
LDH (U/L), median (range) (n = 79) | 696 (75–6332) |
Blasts in BM (%), median (range) (n = 126) | 59.5 (1.0–98.4) |
Prior history of CP diagnosis, n (%) (n = 135) |  |
  Yes | 103 (76.3) |
  No | 32 (23.7) |
Time from CP diagnosis (m), median (range) (n = 93) | 34.3 (0.27–363) |
Age at CP diagnosis (y), median (range) (n = 92) | 45 (14–85) |
Prior TKI before BC, n (%) (n = 134) |  |
  Yes | 57 (42.5) |
  No | 77 (57.5) |
TKIs used for CP, n (%) (n = 53) |  |
  Imatinib | 50 (94.3) |
  Dasatinib | 2 (3.8) |
  Nilotinib | 1 (1.9) |
TKI-based therapy for BC, n (%) (n = 119) |  |
  Yes | 72 (60.5) |
  No | 47 (39.5) |
TKIs used for BC, n (%) (n = 72) |  |
  Imatinib | 36 (50.0) |
  Dasatinib | 32 (44.4) |
  Nilotinib | 2 (2.8) |
  Ponatinib | 2 (2.8) |
Final status, n (%) (n = 123) |  |
  Alive | 26 (21.1) |
  Dead | 97 (78.9) |
Method, n (%) (n = 136) |  |
  Whole-exome sequencing | 76 (55.9) |
  Targeted capture sequencing | 60 (44.1) |
Median follow-up time (m), median (range) (n = 123) | 38.2 (0.13–365) |
